Trikafta, which was approved in 2019 and works for about 90% of patients with the deadly genetic disease, had an annual list price of more than $326,000 in the United States at the end of last year.
In a social media landscape shaped by hashtags, algorithms, and viral posts, nurse leaders must decide: Will they let the narrative spiral, or can they adapt and join the conversation?
...
